The Company’s lead program MANF is aimed at developing products to address the underlying Programmed Cell Death (Apoptosis) associated a wide range of devastating human disorders which include parkinson's, alzheimer's, ischemic heart disease, and traumatic brain injury. All I am saying is it only takes one big-time investor to believe in this company and move the clinical trials forward so we at least see what this MANF is all about.
News 
Market Data 
Discover 
AI
